Analyst Ratings for [SRPT] Sarepta Therapeutics, Inc.

7/28/25	Downgrades	Eq Weight Underweight	X
SRPT Sarepta Therapeutics Barclays
$10
7/25/25	Downgrades	Neutral Underweight	X
SRPT Sarepta Therapeutics JP Morgan
7/24/25	Initiated	Sell	X
SRPT Sarepta Therapeutics Citigroup
$7
7/23/25	Downgrades	Neutral Underperform	X
SRPT Sarepta Therapeutics BofA Securities
$10
7/22/25	Downgrades	Overweight Eq Weight	X
SRPT Sarepta Therapeutics Barclays
$18
7/21/25	Downgrades	Buy Hold	X
SRPT Sarepta Therapeutics Deutsche Bank
$9
7/21/25	Downgrades	Outperform Mkt Perform	X
SRPT Sarepta Therapeutics Leerink Partners
$10
7/21/25	Downgrades	Outperform Neutral	X
SRPT Sarepta Therapeutics Mizuho
$14
7/21/25	Downgrades	Hold Underperform	X
SRPT Sarepta Therapeutics Needham
7/21/25	Downgrades	Buy Neutral	X
SRPT Sarepta Therapeutics UBS
$12
7/18/25	Downgrades	Buy Hold	X
SRPT Sarepta Therapeutics Needham
6/20/25	Downgrades	Outperform Mkt Perform	X
SRPT Sarepta Therapeutics William Blair
6/18/25	Downgrades	Buy Hold	X
SRPT Sarepta Therapeutics TD Cowen
$24
6/17/25	Initiated	Peer Perform	X
SRPT Sarepta Therapeutics Wolfe Research
6/16/25	Downgrades	Outperform Mkt Perform	X
SRPT Sarepta Therapeutics BMO Capital Markets
$70
6/16/25	Downgrades	Buy Neutral	X
SRPT Sarepta Therapeutics BofA Securities
6/16/25	Downgrades	Overweight Neutral	X
SRPT Sarepta Therapeutics Cantor Fitzgerald
6/16/25	Downgrades	Neutral Sell	X
SRPT Sarepta Therapeutics H.C. Wainwright
$10
6/16/25	Downgrades	Overweight Eq-Weight	X
SRPT Sarepta Therapeutics Morgan Stanley
6/16/25	Downgrades	Overweight Neutral	X
SRPT Sarepta Therapeutics Piper Sandler
$36
6/6/25	Upgrades	Sec Perform Sec Outperform	X
SRPT Sarepta Therapeutics Scotiabank
5/8/25	Downgrades	Outperform In-line	X
SRPT Sarepta Therapeutics Evercore ISI
$50
4/11/25	Initiated	Overweight	X
SRPT Sarepta Therapeutics Wells Fargo
$115
4/2/25	Upgrades	Sell Neutral	X
SRPT Sarepta Therapeutics H.C. Wainwright
$75
3/31/25	Downgrades	Outperform Sec Perform	X
SRPT Sarepta Therapeutics RBC Capital Mkts
$161 $87
2/11/25	Initiated	Hold	X
SRPT Sarepta Therapeutics Deutsche Bank
$136
11/27/24	Reiterated	Buy	X
SRPT Sarepta Therapeutics Needham
$205 $202
11/25/24	Initiated	Sell	X
SRPT Sarepta Therapeutics H.C. Wainwright
$80
11/7/24	Upgrades	Neutral Overweight	X
SRPT Sarepta Therapeutics Cantor Fitzgerald
$152 $167
10/21/24	Initiated	Buy	X
SRPT Sarepta Therapeutics Jefferies
$165
10/10/24	Resumed	Outperform	X
SRPT Sarepta Therapeutics Raymond James
$150
7/29/24	Upgrades	Sec Perform Outperform	X
SRPT Sarepta Therapeutics RBC Capital Mkts
$182
6/26/24	Downgrades	Buy Neutral	X
SRPT Sarepta Therapeutics Citigroup
$172 $176
5/31/24	Initiated	Overweight	X
SRPT Sarepta Therapeutics Piper Sandler
$157
5/28/24	Downgrades	Outperform Sec Perform	X
SRPT Sarepta Therapeutics RBC Capital Mkts
$157 $142
5/14/24	Upgrades	Perform Outperform	X
SRPT Sarepta Therapeutics Oppenheimer
$180
1/31/24	Initiated	Outperform	X
SRPT Sarepta Therapeutics BMO Capital Markets
$170
12/13/23	Resumed	Buy	X
SRPT Sarepta Therapeutics Citigroup
$113
12/12/23	Initiated	Buy	X
SRPT Sarepta Therapeutics Deutsche Bank
$109
11/21/23	Initiated	Outperform	X
SRPT Sarepta Therapeutics Wedbush
$224
10/31/23	Downgrades	Overweight Neutral	X
SRPT Sarepta Therapeutics Cantor Fitzgerald
$166 $40
10/31/23	Downgrades	Outperform Perform	X
SRPT Sarepta Therapeutics Oppenheimer
6/23/23	Downgrades	Outperform In-line	X
SRPT Sarepta Therapeutics Evercore ISI
$139
4/26/23	Initiated	Outperform	X
SRPT Sarepta Therapeutics SMBC Nikko
$185
4/4/23	Initiated	Buy	X
SRPT Sarepta Therapeutics Citigroup
$179
3/1/23	Upgrades	Eq-Weight Overweight	X
SRPT Sarepta Therapeutics Morgan Stanley
$141 $187
12/22/22	Reiterated	Buy	X
SRPT Sarepta Therapeutics BTIG Research
$125 $160
12/16/22	Upgrades	Neutral Buy	X
SRPT Sarepta Therapeutics UBS
$100 $158
1/5/22	Reiterated	Buy	X
SRPT Sarepta Therapeutics Needham
$157 $150
12/9/21	Upgrades	Perform Outperform	X
SRPT Sarepta Therapeutics Oppenheimer
$125
11/5/21	Upgrades	Neutral Overweight	X
SRPT Sarepta Therapeutics JP Morgan
$130
6/15/21	Initiated	Buy	X
SRPT Sarepta Therapeutics BTIG Research
$110
4/26/21	Resumed	Neutral	X
SRPT Sarepta Therapeutics Credit Suisse
$72
1/12/21	Downgrades	Buy Neutral	X
SRPT Sarepta Therapeutics Citigroup
$215 $108
1/11/21	Downgrades	Buy Neutral	X
SRPT Sarepta Therapeutics UBS
1/8/21	Downgrades	Overweight Underweight	X
SRPT Sarepta Therapeutics JP Morgan
$96
1/8/21	Downgrades	Overweight Eq-Weight	X
SRPT Sarepta Therapeutics Morgan Stanley
$95
1/8/21	Downgrades	Outperform Mkt Perform	X
SRPT Sarepta Therapeutics Raymond James
7/9/19	Reiterated	Overweight	X
SRPT Sarepta Therapeutics Morgan Stanley
$165 $220
7/1/19	Reiterated	Outperform	X
SRPT Sarepta Therapeutics RBC Capital Mkts
$188 $220
4/12/19	Initiated	Outperform	X
SRPT Sarepta Therapeutics Evercore ISI
3/11/19	Reiterated	Outperform	X
SRPT Sarepta Therapeutics Credit Suisse
$189 $207
10/12/18	Initiated	Outperform	X
SRPT Sarepta Therapeutics Bernstein
10/1/18	Initiated	Overweight	X
SRPT Sarepta Therapeutics Cantor Fitzgerald
$217
9/26/18	Reiterated	Outperform	X
SRPT Sarepta Therapeutics RBC Capital Mkts
$187 $200
9/14/18	Resumed	Buy	X
SRPT Sarepta Therapeutics BofA/Merrill
$199
9/6/18	Initiated	Outperform	X
SRPT Sarepta Therapeutics Credit Suisse
$178
8/1/18	Upgrades	Eq-Weight Overweight	X
SRPT Sarepta Therapeutics Morgan Stanley
6/21/18	Reiterated	Outperform	X
SRPT Sarepta Therapeutics Robert W. Baird
$120 $202
6/20/18	Reiterated	Buy	X
SRPT Sarepta Therapeutics Needham
$109 $204
6/19/18	Reiterated	Buy	X
SRPT Sarepta Therapeutics H.C. Wainwright
$96 $267
5/18/18	Reiterated	Buy	X
SRPT Sarepta Therapeutics Goldman
$84 $127
5/11/18	Upgrades	Eq Weight Overweight	X
SRPT Sarepta Therapeutics Barclays
$55 $107
5/7/18	Reiterated	Buy	X
SRPT Sarepta Therapeutics H.C. Wainwright
$90 $96
5/7/18	Reiterated	Buy	X
SRPT Sarepta Therapeutics Needham
$75 $109
3/21/18	Downgrades	Overweight Eq-Weight	X
SRPT Sarepta Therapeutics Morgan Stanley
3/13/18	Reiterated	Buy	X
SRPT Sarepta Therapeutics H.C. Wainwright
$75 $92

SRPT Sarepta Therapeutics, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.